Entresto(Sacubitril/Valsartan)
NVS
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Novartis AG
$4.02B
Medicare cost, 2024
$4.02B
Medicare cost, 2024
Medicare drug plans spent $4.0 billion on Entresto (sacubitril/valsartan) in 2024, for 3.9 million prescriptions and refills filled by 795,090 patients. It ranks 11th among all drugs by Medicare drug plan spending. Spending rose 17% from 2023 to 2024. Florida accounts for the most spending ($359.1 million, 9% of the total).
Medicare cost, 2024
$4.02B
+17.2% from 2023
Prescriptions
3.9M
$1,031.18 per claim
Patients
795K
216,604 prescribers
Total spending, 2024
$4.02B
$5,055.16 per patient
Questions and answers
How much does Medicare spend on Entresto?
Medicare prescription drug plans paid $4.02B for Entresto in 2024, for 3,897,762 prescriptions and refills to 795,090 patients (up 17.2% from 2023). The average cost per claim was $1,031.18.
Which state spends the most on Entresto?
Florida had the highest Medicare cost for Entresto in 2024: $359.1M for 330,367 claims, followed by California ($355.1M).
Who prescribes Entresto the most?
Haroutioun D Mesrobian, cardiology in Glendale, CA, had the highest Medicare cost for Entresto in 2024: 2,531 claims costing $1.8M.
Who makes Entresto?
Entresto is made by Novartis AG (NVS), listed in the Medicare spending data as Novartis.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Entresto was $4.02B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Entresto, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Haroutioun D Mesrobian Glendale, CA | Cardiology | 2,531 | 301 | $1.8M |
| David H Lau New York, NY | Cardiology | 1,960 | 294 | $1.6M |
| Glenn H Herrington Wilmington, NC | Pharmacist | 836 | 277 | $1.4M |
| Mohamed H Khan Redding, CA | Interventional Cardiology | 927 | 282 | $1.4M |
| John T Funai Lihue, HI | Cardiology | 844 | 257 | $1.3M |
| Sohaib Tariq Imperial, CA | Cardiology | 1,614 | 437 | $1.3M |
| Chetan Bhardwaj Peoria, IL | Cardiology | 1,058 | 243 | $1.2M |
| Robert D Miles Jr. Thomasville, GA | Cardiology | 1,444 | 283 | $1.2M |
| Kenneth M Burnham Mobile, AL | Advanced Heart Failure and Transplant Cardiology | 1,133 | 264 | $1.2M |
| Kashyap B Choksi Thomasville, GA | Cardiology | 1,542 | 318 | $1.2M |
| Warren K Stribling Nashville, TN | Advanced Heart Failure and Transplant Cardiology | 1,006 | 257 | $1.1M |
| Dalton S McLean Greensboro, NC | Advanced Heart Failure and Transplant Cardiology | 1,110 | 238 | $1.1M |
| Robert A Gordon Evanston, IL | Advanced Heart Failure and Transplant Cardiology | 824 | 219 | $1.1M |
| Ugochukwu O Egolum Gainesville, GA | Advanced Heart Failure and Transplant Cardiology | 912 | 246 | $1.1M |
| Andrew Darlington Fayetteville, GA | Advanced Heart Failure and Transplant Cardiology | 1,014 | 227 | $1.1M |
| Rajeev R Fernando Sioux Falls, SD | Cardiology | 913 | 220 | $1.1M |
| Dannis E Hood Ringgold, GA | Interventional Cardiology | 1,151 | 280 | $1.1M |
| Humberto C Machado Jr. Coral Gables, FL | Cardiology | 1,152 | 339 | $1.1M |
| Giancarlo Acosta Gainesville, GA | Advanced Heart Failure and Transplant Cardiology | 933 | 251 | $1.0M |
| Ataul M Qureshi Canton, OH | Cardiology | 927 | 219 | $1.0M |
| Tonya D Baker Kingsport, TN | Nurse Practitioner | 1,161 | 256 | $1.0M |
| Ali M Nasur El Paso, TX | Cardiology | 697 | 243 | $1.0M |
| Catherine N Marti Athens, GA | Cardiology | 774 | 181 | $1.0M |
| Samir A Hadeed Johnstown, PA | Cardiology | 1,016 | 211 | $994K |
| Munir S Janmohamed Sacramento, CA | Advanced Heart Failure and Transplant Cardiology | 808 | 200 | $989K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 158,510 | 2,527,114 | 520,741 | $2.49B |
| 2023 | 190,753 | 3,198,752 | 663,207 | $3.43B |
| 2024 | 216,604 | 3,897,762 | 795,090 | $4.02B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Novartis | 3,898,804 | $4.02B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 15
- RxNorm concept IDs
- 1656340, 1656346, 1656349, 1656351, 1656354
- Application numbers
- NDA207620, NDA218591
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 116,184 side-effect reports named sacubitril and valsartan, the active ingredient of Entresto (reports from 2013 on). 59,720 of them (51.4%) were serious, 14,200 named a death and 21,241 named a hospital stay. The reactions named most often were hypotension, death and dyspnoea. 46,363 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
116,184
3,594 in 2025 (-21.9% from 2024)
Serious
51.4%
59,720 reports
Deaths named
14,200
12.2% of reports
Hospital stays
21,241
18.3% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Entresto?
116,184 reports from 2013 through September 2026 named sacubitril and valsartan, the active ingredient of Entresto. 59,720 of them (51.4%) were serious, 14,200 named a death and 21,241 named a hospital stay.
What are the most reported side effects of Entresto?
11,679 reports named hypotension, the reaction named most often, followed by death (9,164) and dyspnoea (9,055). In the last 5 years the reaction named most often was hypotension (4,312 reports). A report can name several reactions.
How many side-effect reports named Entresto in 2025?
3,594 reports were received in 2025 (-21.9% from 2024). 2026 so far: 2,216 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Entresto caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Entresto caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
NVS·NVS drug pipeline - Drug approvals (2 approvals on file for sacubitril and valsartan) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (sacubitril and valsartan) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.